This Pre-Solicitation opportunity from Department Of Health And Human Services was posted on November 22, 2024. The submission period has ended. Browse the details below for market research, or find similar active opportunities.

Top

Chemistry, Manufacturing and Controls and Related Services for Development of Drug Products

Closed

PS75N95025R00005Federal

Submission Closed11/29/2024, 08:00:00 PM UTC

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

Active Opportunities Like This One

NAICS: 325412

New

International

Pralidoxime Chloride/Methyl Sulfate ManufacturingThis subcontract involves the manufacture and supply of Pralidoxime chloride or methyl sulfate in solution or powder form for injection to support prime contractors on Department of National Defence projects. The required product must have a dosage strength of at least 200 mg per container and a minimum shelf-life of 36 months. The selected provider is responsible for conducting stability testing, providing quality assurance certification, and delivering complete treatment courses along with stability reports and product monographs. To be eligible, the manufacturer must hold a Health Canada Notice of Compliance under Division 8 or Division 11 authorization. This global procurement opportunity is managed by the Government of Canada and allows for performance across various international regions. Interested parties must submit their responses by November 10, 2026.

Department of National Defence

POSTED

DEADLINE

SLS Printer Consumables and Maintenance KitsThis subcontract focuses on the provision of specialized consumables and wear-and-tear replacement parts to support prime contractors working on Department of National Defence projects for the Government of Canada. The scope of supply includes engineering-grade thermoplastic powders such as PA 11, PA 12, PP, and TPU, along with critical SLS hardware components including optical cassettes, recoater blades, infrared heaters, sealing foam gaskets, and build chambers. All bulk consumables and spare parts kits are to be delivered to CFB Petawawa. The opportunity was posted on October 20, 2026, with a response deadline of November 2, 2026, falling under NAICS code 325412.

Department of National Defence

POSTED

DEADLINE

Supplier of Red Sealing Compound (NSN 8030015650423)This subcontract involves the supply of red sealing compound, identified by NSN 8030015650423, for prime contractors working under the Defense Logistics Agency. The material must be provided in 10.00 milliliter containers and strictly adhere to the DLA Master List of Technical and Quality Requirements RA001. The supplier is responsible for managing TYPE I (CODE H) shelf-life requirements and ensuring all packaging complies with MIL-STD-2073-1E and MIL-STD-129 standards. Additionally, the contractor must provide all necessary safety documentation, including SDS and HazCom labels in accordance with 29 C.F.R. 1910.1200. The performance of this contract is centered in FPO 09591-0100, with the primary objective being the delivery of packaged sealing compound and its associated safety certifications to the Department of Defense.

Defense Logistics Agency

POSTED

DEADLINE

Active Pharmaceutical Ingredient (API) SupplyThis subcontract for Active Pharmaceutical Ingredient (API) Supply involves the synthesis, purification, and bulk delivery of pharmaceutical-grade Benzocaine and Menthol. The provider supports prime contractors fulfilling requirements for the Department of Defense Medical Supply Chain Pharm FSA, ensuring all raw chemical components meet strict USP and ISO manufacturing standards through the use of HPLC purity testing. The performance of this contract is centered at Fort Campbell, Kentucky, under NAICS code 325412. The solicitation was posted on October 19, 2026, with a response deadline of October 26, 2026.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

Benzocaine and Menthol Lozenge SupplyThis subcontract involves the manufacture and supply of finished Benzocaine and Menthol lozenges to prime contractors supporting the Department of Defense Medical Supply Chain Pharm FSA. The provider is responsible for producing and quality-testing pharmaceutical lozenges within FDA-compliant facilities adhering to Good Manufacturing Practice standards to ensure all delivered quantities meet strict government specifications. Administrative processes for this requirement are managed through the DLA Internet Bid Board System for quote submissions. The performance of the contract is centered at Fort Campbell, and the procurement falls under NAICS code 325412 for pharmaceutical preparation.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

Supply of Moxifloxacin Hydrochloride Tablets (400 MG)This subcontract, managed by the Medical Supply Chain Pharm FSA under the Department of Defense, involves the manufacture and supply of pharmaceutical-grade Moxifloxacin Hydrochloride Tablets (400 MG). The contractor is responsible for providing the antibiotic tablets in 30-count bottles, ensuring all products are sourced or manufactured in accordance with Good Manufacturing Practices and FDA approval and registration requirements. Logistical compliance is critical, as the contract mandates adherence to RP001 DLA Packaging Requirements and the use of climate-controlled storage and transport to maintain product integrity. Performance will take place in FPO 09591, with the primary objective of supporting prime contractors on DLA supply contracts.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

Supply of Activated Charcoal, SuspensionThis subcontract, issued by the Medical Supply Chain Pharm FSA under the Department of Defense, requires the provision of activated charcoal in suspension form, identified by NSN 6505012828880. The materials must be delivered to the USS Lewis B Puller ESB 3, with all shipments adhering to strict DLA packaging requirements and technical specifications. The contract falls under NAICS code 325412 and is intended for prime contractors supporting DLA supply operations. Resellers are specifically required to comply with the Non-Manufacturer Rule to ensure eligibility. The performance location is designated as FPO 09591, with a response deadline set for October 26, 2026.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

Supply of 4% Chlorhexidine Gluconate Surgical DetergentThis subcontract involves the supply of FDA-regulated 4% Chlorhexidine Gluconate surgical detergent for prime contractors supporting Department of Defense supply contracts. The provider is responsible for manufacturing or sourcing the chemical compound in strict accordance with NSN 6505-01-101-3759 specifications and DLA Packaging Requirements RP001. To maintain quality and regulatory compliance, the product must be produced in FDA-approved pharmaceutical manufacturing facilities. The contract mandates a total shelf life of 24 months, with a requirement that the detergent possesses at least 21 months of remaining shelf life at the time of delivery. Managed under the Medical Supply Chain Pharm FSA, the performance of this contract is centered in FPO 96660, falling under NAICS code 325412.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

Supply of Bupivacaine and Epinephrine InjectionThis subcontract involves the supply of Bupivacaine and Epinephrine Injection to prime contractors supporting DLA Troop Support medical supply contracts. The provider must deliver end items compliant with NSN 6505-01-189-3973, utilizing pharmaceutical-grade materials and medical-grade packaging. To qualify, the supplier is required to hold all necessary pharmaceutical manufacturing licenses and maintain FDA approval for the specific drug formulation. Managed by the Department of Defense under the Medical Supply Chain Pharm FSA, the contract specifies the delivery of injectable medication quantities as outlined in the award. The performance location is designated as FPO 09591, and the procurement falls under NAICS code 325412.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

Isoniazid Tablet ManufacturingThis subcontract involves the manufacturing of Isoniazid 300 MG tablets for prime contractors supporting Department of Defense pharmaceutical supply contracts through the Medical Supply Chain Pharm FSA. The manufacturer is responsible for producing tablets that conform to United States Pharmacopeia standards, packaged in bottles of 100 units. To execute this contract, the provider must utilize pharmaceutical grade API, specialized tablet pressing equipment, and a USP-compliant quality control laboratory. Strict regulatory adherence is required, including the maintenance of active FDA registration and continuous USP compliance. The performance of this contract is centered in FPO 09591, with the primary objective of delivering finished pharmaceutical products that meet all specified government quality and safety benchmarks.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

Tetrahydrozoline Hydrochloride Ophthalmic Solution SupplierThis subcontract involves the supply of Tetrahydrozoline Hydrochloride Ophthalmic Solution, USP (0.05%, 15 ML) to support prime contractors under DLA Troop Support medical supply contracts. The selected provider is responsible for manufacturing or sourcing the pharmaceutical solution in accordance with USP standards, utilizing sterile ophthalmic bottling and packaging. All operations must comply with FDA approval and registration requirements for pharmaceutical manufacturing. The contract is managed by the Department of Defense under the Medical Supply Chain Pharm FSA. Physical deliveries of the ophthalmic solution are to be made to either the prime contractor or the Naval Med Readiness Logistics Command, with the place of performance located in Williamsburg, Virginia.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

Supply of Tolnaftate Powder, USP 1%This subcontract through the Department of Defense Medical Supply Chain Pharm FSA involves the supply of Tolnaftate Powder, USP 1%, to prime contractors on DLA Troop Support medical supply contracts. The requirement is for 15 bottles of 45 GM powder, identified by NSN 6505014807897, which must strictly adhere to USP 1% standards and the DLA Master List of Technical and Quality Requirements. Eligible providers must possess the necessary pharmaceutical manufacturing and distribution licenses to fulfill the order. The performance of this contract is designated for FPO 09591, with a response deadline set for October 26, 2026.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

1 day ago

DEADLINE

in 6 days

AI Contract Overview

The proposed contract, identified by Solicitation Number PS75N95025R00005, aims to offer Chemistry, Manufacturing, and Controls (CMC) services for drug product development under the National Center for Advancing Translational Sciences (NCATS), housed within the NIH. The Therapeutic Development Branch (TDB) at the Division of Preclinical Innovation will lead this initiative, focusing on producing formulated drug products to underpin preclinical, Investigational New Drug (IND)-enabling, and clinical studies. The contract will cover diverse activities, including manufacturing support for drug products and associated materials like placebos and adjuvants, under current Good Manufacturing Practice (cGMP) standards. Deliverables include product formats ranging from small molecules to biologics and novel therapeutic formats as they emerge. The U.S. Government intends to release the Request for Proposals by early December 2024, seeking multiple six-year Indefinite Delivery/Indefinite Quantity (IDIQ) contracts. Successful offerors will engage through cost reimbursement or fixed price task orders that support DPI programs and potentially other NCATS activities of varying scales. An emphasis on maintaining intellectual property control by DPI contributors stands as a unique feature, with relevant clauses deviating from traditional FAR requirements. The anticipated contract awards are expected in the third quarter of FY2025, underlining the significant roles of collaboration and innovation in advancing the drug development process. Such partnerships aim to drive new therapies from discovery through critical preclinical phases and prepare them for regulatory submissions to the FDA.

General Info

Contract for CMC services to support drug development under NCATS; proposals due December 2024.

Agency

Department Of Health And Human Services → NATIONAL INSTITUTES OF HEALTH

NAICS

325412 - Pharmaceutical Preparation Manufacturing

Place of Performance

Rockville, MD, 20850, USA

Set-Aside

NONE

Documents

NCATS TDB - CMC Drug Product Development SOW

sow

High

AI Contract Breakdown

Uniform Contract Format

Contract not broken down yet

CLEATUS splits the solicitation into Uniform Contract Format (UCF) sections: scope, pricing, deliverables, and evaluation criteria.

Timeline

PhaseClosed

PostedNov 15

Presolicitation

Response DeadlineNov 29

Deadline has passed

Submission Closed

11/29/2024, 08:00:00 PM UTC

Find active opportunities like this

Start your free trial to discover similar active contracts, track opportunities, and build proposals with AI assistance.

Organization & Contact Information

AgencyDepartment Of Health And Human Services → NATIONAL INSTITUTES OF HEALTH

Contacts2 people available

OfficeBETHESDA, MD, 20892, USA

Organization / AgencyDepartment Of Health And Human Services → NATIONAL INSTITUTES OF HEALTH

Office AddressBETHESDA, MD, 20892, USA

Contacts

Michelle Cecilia

Valerie Whipple

Full Description

Notice Type: Pre-Solicitation

Solicitation Number: PS75N95025R00005

Project Title: Chemistry, Manufacturing and Controls and Related Services for Development of Drug Products

Classification Code: AN12 - Health R&D Services; Health care services; Applied Research

NAICS Code: 325412 - Pharmaceutical Preparation Manufacturing

SUMMARY:

This is a notice of a proposed contract action issued in accordance with FAR 5.203(a). The Government intends to issue RFP No. 75N95025R00005, titled “CHEMISTRY MANUFACTURING AND CONTROLS AND RELATED SERVICES FOR DEVELOPMENT OF DRUG PRODUCTS,” via SAM.Gov on or about November 30, 2024.

REQUIREMENT AND TYPE OF SERVICE

The Therapeutic Development Branch (TDB) within the Division of Preclinical Innovation (DPI) at the National Center for Advancing Translational Sciences (NCATS) conducts translational research in the area of human therapeutics development.
The scope of this contract is for Chemistry, Manufacturing, and Control (CMC) services for Drug Products. The objective of these support services is to ensure receipt of formulated Drug Product (DP) of sufficient quality and quantity to support preclinical, IND-enabling and clinical studies. For detailed information, see Attachment 1-Statement of Work.

The Contractor shall provide support for a broad range of preclinical services required for the design, development, manufacture, and release of DP, and release of DP as Clinical Trial Material (CTM), including precursors, preliminary states, Reference Standards (RS) and all required testing. Ancillary products (e.g., placebos, diluents, adjuvants, master cell banks, testing standards, reference materials) and other materials manufactured or purchased to support clinical trials or CMC activities may also be required. All activities preliminary to manufacturing in accordance with current Good Manufacturing Practice (cGMP) may be required (e.g., development or engineering lots, formulation studies), even without an associated cGMP manufacturing task. All activities required to maintain material in a usable state, including storage, shipping, testing (in process, release, stability, and quality actions), and preparation of documents to support regulatory submissions may also be required.

Product formats may include small molecules, short oligomeric compounds, biological (large) molecules, quaternary molecular assemblies (homogenous or heterogenous), vectors for gene therapy, nanoparticles, and any of the above modified genetically, biologically, or chemically. Novel formats identified after this draft might also be needed. Formats could also include Devices or Combination Products.

While this contract will be primarily in support of the DPI drug development programs, this contract may include support for a range of NCATS activities differing in size, complexity, and duration.

RELEASE OF SOLICITATION
The Government intends to issue a Request for Proposals on or about December 2, 2024. All information required for the submission of a proposal will be contained in or accessible through the RFP package.

The Government anticipates making multiple, six-year, Indefinite Delivery/Indefinite Quantity (ID/IQ) type contract awards. This is a Ramp-On to an IDIQ that was awarded in August 2024 —with the eventual contracts being administered and funded via Task Orders (TO). The Government may award either cost reimbursement and/or fixed price task orders under this contract. The Government anticipates that at least one task order will be awarded at the time of award. The Government also anticipates the use of Options to Extend the Period of Performance and Options for Increased Quantities negotiated and established at the individual task order level. Each task order shall be individually negotiated at the time of evaluation, prior to award.

The ultimate goal of DPI and this planned project is to bring new drugs to market. To this end, the Government has issued a Determination of Exceptional Circumstances (DEC) to deviate from the Federal Acquisition Regulation clauses at 52.227-11 Patent Rights and 52.227-14 Rights in Data. The deviated language enables DPI contributors to retain control of their intellectual property and will be included in the RFP and incorporated in any resultant contract. Prospective Offerors are advised that agreement to the terms of these FAR clause deviations will be a condition for contract award.

The Government will select the proposal that is most advantageous to the Government in accordance with the basis of award included in the solicitation.

The Government anticipates awards will be made in the third quarter of FY2025.
Based upon market research, the Government is not using the policies contained in Part 12, Acquisition of Commercial Items, in its solicitation for the described supplies or services. However, interested persons or organizations may identify to the Contracting Officer their interest and capability to satisfy the Government's requirement with a commercial item within 15 days of this notice.

THIS IS NOT A REQUEST FOR COMPETITIVE PROPOSALS. However, interested parties may identify their interest and capability to respond to this notice. This advertisement does not commit the Government to award a contract.

ABOUT TDB, DPI AND NCATS

The Therapeutic Development Branch (TDB) within the Division of Preclinical Innovation (DPI) at the National Center for Advancing Translational Sciences (NCATS) within the National Institutes of Health (NIH) conducts translational research to support therapeutic development by moving small molecule and biologic drug candidates forward in the drug development pipeline. Upon reaching predetermined milestones, TDB hands offclinical candidates to external partners to bring these novel therapies to patients. In addition to developing new candidate drugs, TDB seeks to advance the entire field of drug discovery and development by encouraging scientific and technological innovations aimed at improving success rates in the crucial preclinical stage of drug development. The TDB model is to operate as a comprehensive small molecule and biologics drug development organization, moving therapeutic candidates through each phase of the preclinical development process until an Investigational New Drug (IND) application is filed with the US Food and Drug Administration (FDA). For certain drug development campaigns, TDB will support studies up to human Phase IIb. TDB conducts drug development through collaborations, with therapeutic candidates originating from academia, industry, non-profit foundations, or internally from NCATS and other NIH institutes. TDB's operational strategy is to combine the capabilities of in-house staff and collaborative partners with complementary support from contract research organizations (CROs). Each development program operates in a multi-disciplinary matrix team environment, with NCATS responsible for overall planning and execution.

CONTRACTING OFFICE ADDRESS:

National Institutes of Health
National Institute on Drug Abuse (NIDA), Office of Acquisition
C/O NIH Mail Center
NIDA 3WFN MSC 6023
16071 Industrial Drive
Gaithersburg, MD 20877 (20892 for USPS)

Primary Point of Contact:

Michelle Cecilia
Contract Specialist
Michelle.Cecilia@nih.gov
Phone: 301-8727-7199

Secondary Point of Contract:

Valerie Whipple
Contracting Officer
valerie.whipple@nih.gov
phone: 301-827-5218